Tuberculosis-HIV co-infection: progress and challenges after two decades of global antiretroviral treatment roll-out

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Letang Jiménez de Anta, Emilio Ángel
• dc.contributor.author Ellis, Jayne
• dc.contributor.author Naidoo, Kogieleum
• dc.contributor.author Casas, Esther C.
• dc.contributor.author Sánchez-Martínez, Francesca
• dc.contributor.author Hassan-Moosa, Razia
• dc.contributor.author Cresswell, Fiona
• dc.contributor.author Miró, José María
• dc.contributor.author García-Basteiro, Alberto L.
• dc.date.accessioned 2021-04-12T07:05:07Z
• dc.date.available 2021-04-12T07:05:07Z
• dc.date.issued 2020
• dc.description.abstract Despite wide antiretroviral scale-up during the past two decades resulting in declining new infections and mortality globally, HIV-associated tuberculosis remains as a major public health concern. Tuberculosis is the leading HIV-associated opportunistic infection and the main cause of death globally and, particularly, in resource-limited settings. Several challenges exist regarding diagnosis, global implementation of latent tuberculosis treatment, management of active tuberculosis, delivery of optimal patient-centered TB and HIV prevention and care in high burden countries. In this article we review the advances on pathogenesis, diagnosis, and treatment after nearly two decades of global roll-out of antiretroviral therapy and discuss the current challenges for the global control of tuberculosis-HIV co-infection.
• dc.format.mimetype application/pdf
• dc.identifier.citation Letang E, Ellis J, Naidoo K, Casas EC, Sánchez P, Hassan-Moosa R, et al. Tuberculosis-HIV co-infection: progress and challenges after two decades of global antiretroviral treatment roll-out. Arch Bronconeumol. 2020 Jul; 56(7):446-54. DOI: 10.1016/j.arbres.2019.11.015
• dc.identifier.doi http://dx.doi.org/10.1016/j.arbres.2019.11.015
• dc.identifier.issn 0300-2896
• dc.identifier.uri http://hdl.handle.net/10230/47083
• dc.language.iso eng
• dc.publisher Elsevier
• dc.rights © 2019 The Authors. Published by Elsevier España, S.L.U. on behalf of SEPAR. This is an open accessarticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
• dc.subject.keyword ART
• dc.subject.keyword Diagnosis
• dc.subject.keyword Diagnóstico; HIV/AIDS
• dc.subject.keyword Implementation challenges
• dc.subject.keyword Pathogenesis
• dc.subject.keyword Patogénesis
• dc.subject.keyword Resource-limited settings
• dc.subject.keyword Retos en implementación
• dc.subject.keyword Situaciones de recursos limitados
• dc.subject.keyword TARV
• dc.subject.keyword Tratamiento
• dc.subject.keyword Treatment
• dc.subject.keyword Tuberculosis
• dc.subject.keyword VIH/SIDA
• dc.title Tuberculosis-HIV co-infection: progress and challenges after two decades of global antiretroviral treatment roll-out
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion